Drug intelligence / Profile preview

PIKA Rabies Vaccine (human diploid cell)

Development stage: Preclinical
Lead developer: LakeShore Biopharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Intradermal

Overview

**PIKA Rabies Vaccine (human diploid cell)** is a LakeShore Biopharma preclinical rabies vaccine candidate produced using human diploid cells and incorporating the company's PIKA technology. It is intended to induce protective active immunity against rabies virus infection. The exact rabies antigen composition, administration route, dosage form, and detailed PIKA adjuvant composition have not been publicly specified for this human diploid-cell candidate. ([en.lakeshorebio.com](https://en.lakeshorebio.com/index.php?a=index&aid=97&c=View&m=home))

Other names: PIKA rabies vaccine (human diploid cells)

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on PIKA Rabies Vaccine (human diploid cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PIKA Rabies Vaccine (human diploid cell).

Explore the full profile